Stock Analizagilon health, inc. AGL
Misc Health and Biotechnology Services · IPO 2021 · data as of November 13, 2026
agilon health, inc. (AGL) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $6.0B and net income of -$87M, a net margin of -1.5%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 37% a year, a 5-year average ROIC of -65%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 73% below the current price.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0B | $5.9B | $6.1B | $4.3B | $2.4B | $1.5B | $1.2B | $794M |
| Net income | -$87M | -$391M | -$260M | -$263M | -$107M | -$406M | -$60M | -$283M |
| Free cash flow | -$17M | -$119M | -$71M | -$172M | -$146M | -$155M | -$55M | -$107M |
| EPS (diluted) | $-6.69 | $-24.50 | $-15.25 | $-12.00 | $-5.50 | $-25.75 | $-5.00 | $-23.97 |
| Net margin | -1.5% | -6.6% | -4.3% | -6.1% | -4.5% | -26.7% | -4.9% | -35.6% |
| ROIC | — | -223.8% | -44.8% | -25.7% | -7.6% | -25.5% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $120.25, 4% above the current price; targets range from $85.00 to $146.00; the consensus rating is “Buy”; expected EPS is $2.48 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is agilon health, inc. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 73% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does agilon health, inc. pay a dividend?
Not currently.
Is agilon health, inc. a good stock to buy?
We do not give buy or sell advice. agilon health, inc. scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.